Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:56:38.680Z.
Calculation as of: 2026-10-06T18:56:38.680Z.
Quote observation: 2026-10-06T18:54:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$119.83M
PS Ratio
89.76
TTM Avg
500.86
3Y Avg
500.86
5Y Avg
500.86
Market Cap
$124.98M
PS Ratio
4.29
TTM Avg
11.00
3Y Avg
311.63
5Y Avg
311.63
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $121.25M | N/A | N/A | N/A | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | 8.75 | 7.14 | 7.75 | 61.78 |
| Cibus, Inc. (CBUS)vs › | $122.13M | 28.10 | 25.82 | 87.76 | 78.89 |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.83M | 89.76 | 500.86 | 500.86 | 500.86 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.93M | 5.58 | 34.83 | 63.67 | 63.67 |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.12M | N/A | 28.59 | 17.79 | 17.79 |
| TuHURA Biosciences, Inc. (HURA)vs › | $123.54M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $118.06M | N/A | N/A | N/A | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.98M | 4.29 | 11.00 | 311.63 | 311.63 |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | 14.51 | 42.02 | 39.60 | 39.60 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-10-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-22 |
| Q1 FY2026Period ended 2026-01-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-09 |
| Q2 FY2026Period ended 2026-04-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-15 |
| Q3 FY2026Period ended 2026-07-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-08 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
